Background: Bevacizumab combined with chemotherapy has recently shown promising
efficacy in recurrent high-grade glioma. Phosphatase and tensin homolog (PTEN) mutation …

We evaluated the efficacy of metronomic etoposide or temozolomide administered with
bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior …

Purpose Bevacizumab is an active anti-angiogenic agent in the treatment of recurrent
glioblastoma. Temozolomide can prolong survival in patients with newly diagnosed …

BACKGROUND: The authors performed a phase 2 trial of combined protracted daily
temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had …

2017 Background: The optimal use of bevacizumab (bev) in recurrent glioblastoma (GBM)
remains uncertain including the choice between monotherapy or combination therapy as …

The optimal combination of bevacizumab with cytotoxic or cytostatic drugs in recurrent
glioblastoma is unknown. We performed a phase 2 trial of combined bevacizumab and …

Bevacizumab has demonstrated activity in patients with recurrent glioblastoma. However,
the impact of prognostic factors associated with recurrent glioblastoma treated with cytotoxic …

Objective: To review the available literature evaluating the effect of bevacizumab on
progression-free survival when used in combination with irinotecan for recurrent …

Background Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target
of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma …

Background We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …